142 related articles for article (PubMed ID: 32501652)
1. Progress in the research of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer.
Xian J; Cheng Y; Qin X; Cao Y; Luo Y; Cao Y
J Cell Mol Med; 2020 Jul; 24(13):7451-7459. PubMed ID: 32501652
[TBL] [Abstract][Full Text] [Related]
2. NUMB controls p53 tumour suppressor activity.
Colaluca IN; Tosoni D; Nuciforo P; Senic-Matuglia F; Galimberti V; Viale G; Pece S; Di Fiore PP
Nature; 2008 Jan; 451(7174):76-80. PubMed ID: 18172499
[TBL] [Abstract][Full Text] [Related]
3. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
4. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Cell Tissue Res; 2013 Nov; 354(2):521-32. PubMed ID: 23881403
[TBL] [Abstract][Full Text] [Related]
5. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity.
Liu D; Cui L; Wang Y; Yang G; He J; Hao R; Fan C; Qu M; Liu Z; Wang M; Chen L; Li H; Guo D
Hepatology; 2016 Aug; 64(2):390-404. PubMed ID: 27106262
[TBL] [Abstract][Full Text] [Related]
7. A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
Colaluca IN; Basile A; Freiburger L; D'Uva V; Disalvatore D; Vecchi M; Confalonieri S; Tosoni D; Cecatiello V; Malabarba MG; Yang CJ; Kainosho M; Sattler M; Mapelli M; Pece S; Di Fiore PP
J Cell Biol; 2018 Feb; 217(2):745-762. PubMed ID: 29269425
[TBL] [Abstract][Full Text] [Related]
8. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.
Sczaniecka M; Gladstone K; Pettersson S; McLaren L; Huart AS; Wallace M
J Biol Chem; 2012 Apr; 287(17):14052-68. PubMed ID: 22337874
[TBL] [Abstract][Full Text] [Related]
9. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
10. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.
Tosoni D; Pambianco S; Ekalle Soppo B; Zecchini S; Bertalot G; Pruneri G; Viale G; Di Fiore PP; Pece S
EMBO Mol Med; 2017 May; 9(5):655-671. PubMed ID: 28298340
[TBL] [Abstract][Full Text] [Related]
13. Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Wang G; Sheng W; Tang J; Li X; Zhou J; Dong M
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31898732
[TBL] [Abstract][Full Text] [Related]
14. The Mdm2 oncoprotein interacts with the cell fate regulator Numb.
Juven-Gershon T; Shifman O; Unger T; Elkeles A; Haupt Y; Oren M
Mol Cell Biol; 1998 Jul; 18(7):3974-82. PubMed ID: 9632782
[TBL] [Abstract][Full Text] [Related]
15. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis.
Dhami GK; Liu H; Galka M; Voss C; Wei R; Muranko K; Kaneko T; Cregan SP; Li L; Li SS
Mol Cell; 2013 May; 50(4):565-76. PubMed ID: 23706821
[TBL] [Abstract][Full Text] [Related]
16. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract][Full Text] [Related]
17. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
18. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
19. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
20. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
